Lotus Pharmaceuticals Inc (LTUS)

[Steppenwolf$$$]

FEBRUARY 12, 2019
Alvogen
launches
the
first
generic
equivalent
to
Revlimid™
in
Europe
Alvogen today announced the launch of the first generic equivalent of Revlimid™ (lenalidomide) in several CEE markets including Romania, Croatia, Bulgaria and the Baltic states. The product will be marketed as 2.5, 5, 7.5, 10, 15, 20, 25mg hard capsules and is a fully generic and bioequivalent product to Revlimid™. Following the launch into multiple CEE countries, Alvogen’s Lenalidomide will also be launched in selected Asian countries in 2019.

Alvogen’s Lenalidomide has been developed fully in-house at Alvogen‘s subsidiary, Lotus Pharmaceuticals and is part of a comprehensive oncology pipeline